Furthermore, blockade of the RAAS system by ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) upregulates the expression of ACE2 in patients predisposed to severe SARS‐CoV‐2 infection, such as individuals with heart failure, already displaying abundant ACE2 in their COVID‐19‐target organs, thus potentially sensitizing patients on these medications to the virus.21, 24, 25. The gene discussed is ACE; the disease is heart failure.